Schroder Investment Management Group boosted its position in shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) by 235.0% during the second quarter, Holdings Channel reports. The institutional investor owned 18,592 shares of the biopharmaceutical company’s stock after buying an additional 13,042 shares during the period. Schroder Investment Management Group’s holdings in Alnylam Pharmaceuticals were worth $1,032,000 as of its most recent SEC filing.
Other hedge funds have also recently added to or reduced their stakes in the company. Broderick Brian C boosted its stake in Alnylam Pharmaceuticals by 20.3% in the second quarter. Broderick Brian C now owns 5,982 shares of the biopharmaceutical company’s stock worth $331,000 after buying an additional 1,010 shares during the period. Hemenway Trust Co LLC boosted its stake in Alnylam Pharmaceuticals by 4.1% in the second quarter. Hemenway Trust Co LLC now owns 13,200 shares of the biopharmaceutical company’s stock worth $732,000 after buying an additional 525 shares during the period. Fayerweather Charles boosted its stake in Alnylam Pharmaceuticals by 3.5% in the second quarter. Fayerweather Charles now owns 4,165 shares of the biopharmaceutical company’s stock worth $231,000 after buying an additional 140 shares during the period. Turner Investments L.P. bought a new stake in Alnylam Pharmaceuticals during the second quarter worth approximately $575,000. Finally, Janney Montgomery Scott LLC bought a new stake in Alnylam Pharmaceuticals during the second quarter worth approximately $223,000. Institutional investors and hedge funds own 85.96% of the company’s stock.
Shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) traded down 1.97% during midday trading on Friday, reaching $75.57. 484,655 shares of the company traded hands. The stock’s market capitalization is $6.48 billion. Alnylam Pharmaceuticals Inc. has a 1-year low of $49.96 and a 1-year high of $110.75. The stock’s 50-day moving average is $73.61 and its 200-day moving average is $65.76.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.24) by $0.19. The firm earned $8.70 million during the quarter, compared to the consensus estimate of $8.09 million. Alnylam Pharmaceuticals had a negative return on equity of 29.60% and a negative net margin of 1,204.91%. The firm’s quarterly revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.85) earnings per share. Equities analysts predict that Alnylam Pharmaceuticals Inc. will post ($4.65) EPS for the current fiscal year.
ALNY has been the subject of a number of recent research reports. Credit Suisse Group AG reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, June 12th. Leerink Swann reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, June 12th. Cowen and Company reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, June 12th. Needham & Company LLC reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, June 13th. Finally, FBR & Co reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Friday, June 10th. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Alnylam Pharmaceuticals has an average rating of “Buy” and a consensus target price of $113.62.
In other news, CEO John Maraganore sold 30,151 shares of the stock in a transaction that occurred on Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total value of $1,950,468.19. Following the completion of the sale, the chief executive officer now directly owns 148,465 shares of the company’s stock, valued at $9,604,200.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.00% of the stock is owned by insiders.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.